A Phase 1/2 First in Human Single-arm Open-label Study of Once a Day Orally Administered BMN673 in Patients with Advanced or Recurrent Solid Tumors
-
- STATUS
- Not Recruiting
Updated on 19 February 2024
Summary
The purpose of this study is to test the safety of a new experimental drug called BMN 673 and see what effects it has on cancer.
Description
This is a single-arm, open-label study to assess the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of BMN 673 in patients with advanced tumors with DNA-repair pathway deficiencies. There will be 2 parts to the study: a dose escalati
Details
| Condition | Solid Tumor |
|---|---|
| Age | 18years - 100years |
| Clinical Study Identifier | TX2081 |
| Last Modified on | 19 February 2024 |
How understandable was the trial content above?
Hard to understand
Easy to understand
Similar trials to consider
Loading...
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteerStudy Definition
WikipediaAdd a private note
- Select a piece of text.
- Add notes visible only to you.
- Send it to people through a passcode protected link.